Pharmaceutical Report Library l Report Store l Pharma Intelligence

Rixubis

Developed by Baxalta (which was then acquired by Shire), Rixubis was only the second recombinant factor IX (rfIX) therapy approved for hemophilia B, and the first to be indicated for routine prophylaxis treatment in adults upon its 2013 approval.

May 4, 2018

Find out more

Wound Care: Tissue-Engineered Skin Replacements and Active Wound Repair Modulators

$4,750.00

This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the US, 5EU, Japan, and RoW markets for tissue-engineered skin replacements (epidermal, dermal, and multilayer equivalents, and amniotic tissue grafts) and active wound repair modulators (growth factors, gene therapy agents, and stem cells).

September 23, 2020

Find out more

Pediatric Acute Leukemias (AML/ALL) KOL Interview

$599.00

Highlights Current manufacturing turnaround times for CAR-T products (2-3 weeks) for ALL are not a major limitation for pediatric leukemia patients. CAR-T treatments may be more acutely toxic than transplant immediately after infusion, but patients may have fewer medium- and long-term complications. Agents that target the cell cycle (CDK inhibitors, Aurora kinase inhibitors) will likely […]

April 1, 2015

Find out more

Women’s Health: U.S. Markets for Female Urinary Incontinence Therapies

$3,750.00

This report focuses on minimally invasive therapy systems and medications designed for the treatment of female UI, including OAB pharmaceutical or drug treatments, injectable urethral bulking agents, and urethral sling systems, of which the OAB drug treatments market contributes the vast majority of revenues.

September 22, 2016

Find out more

Diffuse Large B-Cell Lymphoma (DLBCL) KOL Interview – US

$599.00

A US-based key opinion leader (KOL) gives insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for DLBCL. Therapies discussed include Polivy, Monjuvi, Zynlonta, CD19-directed CAR-T therapy and CD20-directed bispecific antibodies.

April 21, 2022

Find out more

Alzheimer’s KOL Interview

$399.00

KOL is optimistic on amyloid-targeted therapy and believes IV therapy will be tolerated if approved.

October 21, 2015

Find out more

DCVAC/PCa

DCVAC/PCa is a cell-based cancer vaccine composed of autologous dendritic cells which are activated to recognize a prostate cancer cell line. When infused into patients, the primed dendritic cells cause activation of T cells…

January 18, 2018

Find out more

Viekira Pak franchise

AbbVie’s Viekira Pak franchise comprises Viekira Pak ([paritaprevir + ritonavir + ombitasvir] + dasabuvir), Viekira XR ([paritaprevir + ritonavir + ombitasvir + dasabuvir]), and Technivie ([paritaprevir + ritonavir + ombitasvir]), which is branded as Viekirax outside the US market.

November 6, 2017

Find out more

Adempas

Adempas (riociguat; Bayer/Merck & Co) is a first-in-class drug that activates soluble guanylyl cyclase (sGC), a key enzyme in nitric oxide-mediated vasodilation of vascular smooth muscle cells.

October 29, 2018

Find out more

Plavix

Plavix is an antiplatelet agent that inhibits blood clot formation. It works by irreversibly binding to the blood platelet’s adenosine diphosphate (ADP) P2Y12 receptor, preventing ADP-mediated activation of the glycoprotein IIb/IIIa complex.

July 2, 2018

Find out more

Tremfya

Tremfya (guselkumab; Johnson & Johnson/MorphoSys) is a fully human immunoglobulin G1-lambda monoclonal antibody that inhibits interleukin (IL)-23-specific intracellular and downstream signaling.

October 17, 2017

Find out more

Daklinza

Daklinza (daclatasvir; Bristol-Myers Squibb) is a first-generation NS5A inhibitor approved for use for the treatment of genotype 1/2/3/4 (GT-1/2/3/4) chronic hepatitis C virus patients. Within the US and five major EU markets (France, Germany, Italy, Spain, and the UK), Daklinza is also approved for use in combination with Sovaldi (sofosbuvir; Gilead) for the treatment of GT-1/3 patients.

November 6, 2017

Find out more

2014 Community-Acquired Pneumonia Pulse

$599.00

We performed a 5-question survey of 20 infectious disease (ID) specialists in the U.S. to gauge current prescribing practices for community-acquired pneumonia (CAP) and gauge interest in new drugs/new drug candidates.

December 18, 2014

Find out more

prostate-cancer-pricing-reimbursement-and-access_162106_10-2016

Prostate Cancer: Market Access Pricing & Reimbursement

$2,995.00

The prostate cancer market has become saturated in the metastatic castration-resistant prostate cancer (CRPC) setting; the approval of second-generation antiandrogens, radiotherapies, and chemotherapies has resulted in a great deal of development targeting earlier stages of the disease.

June 1, 2018

Find out more

Venetoclax

Venetoclax (AbbVie/Roche) is a novel B-cell lymphoma-2 (BCL-2) inhibitor currently being developed

for treatment-naïve and relapsed/refractory chronic lymphocytic leukemia (CLL).

September 11, 2015

Find out more

Ryzodeg

Ryzodeg is a fixed-ratio combination of basal insulin analog Tresiba (insulin degludec) with a bolus of prandial insulin analog NovoLog (insulin aspart). The product received regulatory approval in Japan and the EU in 2013.

November 7, 2017

Find out more

Big Pharma Outlook 2025

$2,700.00

Using in-house sales forecasts, this analysis explores and visualizes market dynamics in the Big Pharma peer set out to 2025.

December 20, 2016

Find out more

ECLIPSE Psoriasis Pulse Survey

$599.00

This 11-question pulse survey of 74 dermatologists practicing throughout the US and Europe asks respondents their thoughts on results from the ECLIPSE study

January 31, 2019

Find out more

LR769

LR769 is a recombinant factor VIIa (rfVIIa) therapy in development by LFB for patients with hemophilia A or B with inhibitors.

May 4, 2018

Find out more

Orencia

Orencia (abatacept; Bristol-Myers Squibb/Ono Pharmaceutical) is a soluble fusion protein that consists of the extracellular domain of human cytotoxic T-lymphocyte antigen-4.

October 17, 2017

Find out more

Bexsero

Bexsero (multicomponent meningococcal serogroup B vaccine; GlaxoSmithKline) is a multicomponent meningococcal serogroup B vaccine. It is approved for the prevention of invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup B in adolescents and young adults from 10 years through to 25 years of age in the US, and in individuals two months of age and older in the EU. Bexsero contains three surface-exposed recombinant proteins: factor H binding protein, Neisseria adhesin A, and Neisseria heparin-binding antigen. It also includes New Zealand strain outer membrane vesicles. The antibodies generated after immunization with Bexsero target the aforementioned surface proteins present on the outer membrane vesicles.

September 3, 2019

Find out more

Disease Analysis: Ulcerative Colitis

Ulcerative colitis (UC) is a form of chronic inflammatory bowel disease (IBD), which causes mucosal inflammation affecting the colon. The idiopathic inflammation is commonly associated with the rectum (proctitis) and may extend proximally, evolving into left-sided
colitis or extensive colitis. UC typically presents with bloody diarrhea, which may manifest alongside mucus, rectal urgency, tenesmus, and abdominal pain. The disease course is relapsing and remitting with intermittent periods of acute exacerbation, which may be serious enough to warrant therapy escalation, hospitalization, or even colectomy.

October 6, 2021

Find out more

Arikayce

Arikayce is a formulation of the antibiotic amikacin that uses Insmed’s liposomal delivery system and is under development for the treatment of lung infections caused by NTM.

September 3, 2018

Find out more

Faslodex

Faslodex (fulvestrant; AstraZeneca) is an analog of 17 beta-estradiol, the dominant circulating estrogen, which competitively inhibits the binding of natural estradiol to the estrogen receptor (ER).

February 2, 2016

Find out more

The Contract Biomanufacturing Market Outlook to 2017

$5,000.00

The biologic drug market is growing at nearly twice the pace of the overall pharmaceutical market, driven by major therapeutic fields under research such as oncology and autoimmune diseases. The forecasted 20% annual increase in biologic active pharmaceutical ingredient (API) demand between 2011 and 2017 combined with the growth of biosimilars will generate a positive environment for the biologics contract manufacturing organization (CMO) market to grow at 9% per year over the same period.

November 3, 2016

Find out more

CRO Snapshot 2013

$5,000.00

An initial study of the only publicly available data detailing clinical trial starts where contract research organizations (CROs) were named as a collaborator in 2013 shows a 10% lessening in work to the service provider industry.

November 3, 2016

Find out more

Q4 2016 Outlook Report

$750.00

In this report, we cover catalysts from 23 drugs, devices and diagnostics expected to occur in Q4 2016. We have also included a list of Large Impact catalysts in the drug and device/diagnostic areas through Q4 2016.

November 16, 2016

Find out more

France, Disease Incidence and Prevalence

$4,850.00

As the aging population in Europe increases and the average life span lengthens, the incidence and prevalence of many major diseases/disorders are expected to increase accordingly and significantly impact the European healthcare industry.

September 22, 2016

Find out more

Q3 2021 Outlook Report

$4,750.00

In this report, we cover catalysts from 27 drugs, devices, diagnostics, and deals expected to occur in the third quarter of 2021. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided. These data points were provided using a combination of Pharmapremia, Informa’s drug development benchmarking product utilizing Biomedtracker’s LOA data to assist in informed decisions about drug pipeline prioritization, partnerships, and acquisitions, and drug approval data from Biomedtracker.

June 2, 2021

Find out more

Ximency

Ximency (Bristol-Myers Squibb) is a twice-daily fixed-dose combination of daclatasvir, a first-generation NS5A inhibitor; asunaprevir, an NS3 protease inhibitor; and beclabuvir, a non-nucleoside NS5B inhibitor. The combination is approved in Japan for the treatment of genotype 1 (GT-1) chronic hepatitis C virus infection.

November 6, 2017

Find out more

Report library

Rixubis

Wound Care: Tissue-Engineered Skin Replacements and Active Wound Repair Modulators

Pediatric Acute Leukemias (AML/ALL) KOL Interview

Women’s Health: U.S. Markets for Female Urinary Incontinence Therapies

Diffuse Large B-Cell Lymphoma (DLBCL) KOL Interview – US

Alzheimer’s KOL Interview

DCVAC/PCa

Viekira Pak franchise

Adempas

Plavix

Tremfya

Daklinza

2014 Community-Acquired Pneumonia Pulse

Prostate Cancer: Market Access Pricing & Reimbursement

Venetoclax

Ryzodeg

Big Pharma Outlook 2025

ECLIPSE Psoriasis Pulse Survey

LR769

Orencia

Bexsero

Disease Analysis: Ulcerative Colitis

Arikayce

Faslodex

The Contract Biomanufacturing Market Outlook to 2017

CRO Snapshot 2013

Q4 2016 Outlook Report

France, Disease Incidence and Prevalence

Q3 2021 Outlook Report

Ximency